Initial treatment choice depends partly on the patient's preference. Tumor models elucidated genetic influence, threshold tissue levels of activity and mechanism of actions. Luteotrope hormone-releasing hormone agonists and antiandrogens are integrated in clinical practice. Imidazole derivations, 5α-reductase blockers and growth-factor antagonists offer clinical potential.